Immunosuppressants such as cyclosporin A (CsA) and 
Some evidence suggests that CsA exerts its survival promoting effects through inhibition of cyclophilin D, which comprises part of the mitochondrial permeability transition pore (MPTP)
. Opening [15] . Although CsA has been shown to reduce infarct size following middle cerebral artery occlusion [13] , FK-506, a drug which lacks effect on the MPTP, also exhibits similar survival promoting properties [16] . Although it is possible that these agents may exert their effects through unrelated mechanisms, their commonality with respect to immune function (inhibition of calcineurin signalling) suggests a potential mechanism [4] .
Interestingly, immunophilin and calcineurin expression are strongly correlated within the CNS, suggesting a functional connection [5, 17] [18] [19] [20] . Bad has previously been shown to influence the release of cytochrome c and other apoptogenic proteins from the mitochondrial intermembraneous space following stimulation of PCD [18] [19] [20] . The phosphorylation status of Bad has been implicated as the primary regulatory mechanism governing this BH3-only protein, because phosphorylation of serine residues S112, S136 and S155 enhance the interaction of Bad with 14-3-3 , which prevents it from translocating to the mitochondria (S112 and S136), or disrupts its inhibition of anti-apoptotic Bcl-xL (S155) [21] [22] [23] [24] .
. A linkage between calcineurin inhibition and neuronal survival is suggested from studies which shown that calcineurin mediates dephosphorylation of Bcl-2 associated death promoter (Bad); a pro-apoptotic Bcl-2 family protein
In the present study, we show that CsA and FK-506 enhanced neuronal survival following axotomy-induced facial motor neuron injury in mice, similar to previous work in rats [25] . We [25, [27] [28] [29] [30] . [32, 33] . Although strain variations exist, this lesion paradigm typically results in a loss of Ͼ80% of facial motor neurons by 1 week after axotomy [33] . In the current study, mice were subjected to unilateral facial nerve axotomy on postnatal day 3 (P3), and given either CsA or FK-506 once daily for 7 days following injury until the time of killing. As shown in Fig. 1 , an enhancement of motor neuron survival was observed in mice following administration of either CsA (20 mg/kg) (Fig. 1C and D) or FK-506 (3 mg/kg) ( Fig. 1E and F) compared to vehicle-treated controls (Fig. 1A and B Fig. 1G 
further demonstrate that a direct inhibition of calcineurin by cypermethrin (which acts independently of immunophilins) also promotes motor neuron survival following axotomy. In contrast, other signalling pathways related to immunophilin functions did not alter motor neuron survival. These data indicate that the survival promoting effects of CsA and FK-506 on motor neurons following injury are a direct consequence of their ability to inhibit the phosphatase activity of calcineurin.
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) within injured facial nuclei (dotted regions). Stereological serial counts of surviving motor neurons were performed through the full extent of the facial nucleus for nuclei on both contralateral (uninjured) and ipsilateral (injured) to the axotomized facial nerve, in order to quantify the effect of drug treatment on axotomized motor neurons. As shown in
CsA and FK-506 protect motor neurons following injury by reducing caspase-3 activation
To better understand the mechanism by which CsA and FK-506 treatments enhance the survival of injured facial motor neurons, we investigated the downstream pattern of PCD progression by examining executioner caspase activation within the facial nucleus. Such caspases have been shown to be proteolytic activated within injured facial motor neurons following neonatal axotomy [34-36]. Inhibition of this response can therefore be taken as evidence of inhibition of PCD in facial motor neurons at a point upstream of executioner caspase activation. For these experiments, levels of caspase-3 activation were examined through the full extent of facial nuclei by stereological counts at 20 hrs following injury (a peak period of injury-induced motor neuron death). Significant elevation in levels of activated caspase-3 was observed in injured as compared to uninjured facial nuclei in vehicle-treated controls (Fig. 2A and B). Administration of CsA (Fig. 2C and D) and FK-506 (Fig. 2E and F) significantly reduced the levels of activated caspase-3 in injured facial nuclei relative to vehicle treatment. Stereological counts of motor neurons expressing activated caspase-3 throughout the facial nucleus demonstrated that both CsA and FK-506 significantly reduced caspase-3 activation (16 Ϯ 2% and 36 Ϯ 3% reduction compared to vehicle, respectively) (Fig. 2G). Interestingly, facial motor neurons expressing activated caspase-3 were significantly increased in uninjured facial nuclei of CsA-treated animals relative to vehicle-treated controls (95 Ϯ 3%) (Fig. 2C and G). In contrast, FK-506 administration did not appear to alter the levels of naturally occurring PCD in uninjured facial nuclei during the same period (Fig. 2E and G).
CsA and FK-506 do not alter levels of reactive gliosis or microglial infiltration following injury
Microglial activation and reactive gliosis are frequently observed following many forms of neural injury, and have been suggested to contribute to levels of neuronal death [37, 38] (Fig. 3) . Similarly, numbers of reactive (GFAP ϩ ) astrocytes within injured facial nuclei were also observed to be comparable between treated and controls groups (Fig. 4) 
. To determine the effect of CsA and FK-506 treatments on these secondary cellular responses, the degree and pattern of reactive gliosis and microglial infiltration were examined in control and treated facial nuclei at 2 (data not shown) and 4 days after injury (Figs 3 and 4). As indicated in the figure, levels of activated microglia present within injured facial nuclei were not altered by either drug treatment
Enhancement in neuronal survival is not mediated via calcineurin-independent signalling pathways
Due to the array of potential cellular interaction targets for both CsA and FK-506, several possible mechanisms of neuronal survival effects exist beyond that of calcineurin inhibition. Recently, several calcineurin-independent signalling pathways have been suggested as possible means by which CsA and FK-506 exert their neuroprotective effects using non-immunosuppressive (calcineurin-independent) immunophilin ligands such as GPI-1046
and V-10,367 [3, 14, [39] [40] [41] . In addition, an alternative calcineurin-independent model of FK-506-mediated neuritic outgrowth has recently been proposed [42, 43] [27, 28, 30] . As shown in Fig. 5 
Role of calcineurin inhibition in CsA-and FK-506-mediated facial motor neuron survival
The absence of survival promoting effects observed following the administration of several calcineurin-independent agents prompted us to investigate the contribution calcineurin inhibition has with respect to neuronal survival in greater detail. To perform manner disparate to that of CsA and FK-506. Cypermethrin, is a type II synthetic pyrethroid insecticide which inhibits calcineurin through direct binding, thus functions as a cyclophilin/FKBP-independent calcineurin inhibitor [44]. To examine the potential of cypermethrin to enhance neuronal survival following injury, cypermethrin (10 mg/kg) was administered to animals on a daily basis following axotomy until the time of killing. Total counts of facial motor neurons demonstrated that cypermethrin treatment significantly enhanced motor neuron survival following axotomy compared to vehicle controls (32 Ϯ 3% versus 12 Ϯ 1%, respectively) (Fig. 6A and B). This represents the first demonstration that cypermethrin and, by extension, direct calcineurin inhibition enhance motor neuron survival following injury in vivo.
CNA isoform ␣ is dispensable for regulating motor neuron survival following injury
6C). Thus, CNA-␣ appears to be dispensable both for developmental and injury-mediated loss of facial motor neurons. Thus the motor neuron survival enhancement observed using CsA, FK-506 and cypermethrin appear to reflect an inhibition which extends beyond CNA-␣ alone, and most probably due to the inhibition of ␤ and ␥ isoforms in facial motor neurons as well.
Inhibition of calcineurin-mediated Bad dephosphorylation by FK-506 and cypermethrin following injury
A previous in vitro study had demonstrated an inhibition of calcineurin-mediated Bad dephosphorylation by FK-506 following glutamate stimulation was correlated with enhanced survival of the stimulated neurons, thus suggesting that inhibition of calcineurinmediated Bad dephosphorylation is, at least partially, responsible for enhanced survival of facial motor neurons following administration of CsA, FK-506 and cypermethrin [19]. To determine whether Bad serine 112 (S112) dephosphorylation occurs within facial motor neurons following axotomy, and whether this process is regulated through calcineurin, we examined levels of S112 Bad phosphorylation by immunofluorescence at 20 hrs following facial nerve axotomy in vehicle, FK-506 and cypermethrin-treated animals. In vehicle-treated animals, Bad S112 phosphorylation was on average reduced in injured facial motor neurons to 55 Ϯ 4% of that observed in the contralateral (uninjured) facial nuclei (Fig. 7). In contrast, FK-506 and cypermethrin-treated animals exhibited substantially reduced levels of Bad S112 dephosphorylation compared to vehicle-treated controls, demonstrating that both treatments inhibited calcineurin-mediated Bad dephosphorylation at serine 112. Although cypermethrin treatment enhanced levels of Bad S112 phosphorylation to 87 Ϯ 11% of that seen in uninjured facial motor neurons, treatment with FK-506 appeared to have completely restored levels of Bad S112 phosphorylation to that observed in the contralateral facial nuclei (100 Ϯ 12%) (Fig. 7). These results support the notion that regulation of Bad phosphorylation status may be a critical PCD signalling event downstream of calcineurin inhibition. The results further suggest that this can occur through either indirect inhibition of the drug-immunophilin complex, or directly through inhibition of calcineurin.
Discussion
In [32, 36] . Rather, the data demonstrate that the neuronal survival effects observed are the result of a cell autonomous reduction in PCD with facial motor neurons. [3, 13] 
Fig 6. CsA and FK-506 do not suppress levels of reactive gliosis following facial axotomy. Sections were labeled with GFAP to examine numbers of reactive astrocytes at 4 days following facial axotomy. (A), (D) and (G) show sections through unoperated facial nuclei (contralateral -con.). (B), (E) and (H) show sections through operated facial nuclei (ipsilateral -ips.). Scale bars represent 500 m. (C), (E) and (I) show injured
Given the immunosuppressive nature of CsA and FK-506, it might be postulated that the observed enhancement in motor neuron survival mediated by these agents is related to their suppression of immunologic phenomena retarding the rate of destruction of facial motor neurons. This is unlikely for several reasons. (1) FK-506 and CsA act to protect motor neurons from cell death over a time period which is incompatible with immunosuppression [48], given that suppression of caspase-3 activity is seen in the facial nucleus by 20 hrs after injury (earliest time-point examined). (2) In addition, if CsA and FK-506-mediated motor neuron survival through suppression of inflammatory responses within the facial nucleus, one would expect cellular processes such as reactive gliosis and infiltration of activated microglia to be suppressed in the presence of these drugs; both of which were not observed in the present study. (3) Finally, if direct or immune-stimulated cell-cell interactions were a significant cause of motor neuron death within the facial nucleus, dying motor neurons would not exhibit the apoptotic morphologic and biochemical features which have previous been well characterized for this lesion paradigm
If the immunophilin ligands CsA and FK-506 act in a cell intrinsic manner to reduce PCD in injured motor neurons, what is the mechanism of these effects? Neuroprotection by CsA has long been rationalized in terms of an inhibitory effect upon MPTP formation through interaction with cyclophilin D
17-AAG and rapamycin treatments do not enhance facial motor neuron survival following injury. (A) Histogram of stereological counts of facial motor neurons from mice treated with 17-AAG (10 mg/kg) or vehicle performed at 4 days after axotomy. Similar to rapamycin, treatment with 17-AAG did not enhance levels of motor neuron survival compared to controls (22 Ϯ 1% versus 25 Ϯ 2% for 17-AAG and vehicle-treated groups, respectively), indicating these respective immunophilin-related pathways are not involved in neuroprotection. (B) depicts a typical injured facial nucleus from an animal treated daily with 17-AAG following axotomy. (C) Histogram of facial motor neuron survival following rapamycin treatment. Mice receiving daily rapamycin administration (3 mg/kg) following injury until time of killing showed no significant difference in motor neuron survival compared to vehicle-treated controls (17 Ϯ 2% versus 13 Ϯ 1%, respectively). Shown in (D) is a typical injured facial nucleus from rapamycin-treated animals.
An alternative mechanism recently proposed to explain the neurotrophic/neuroprotective effects of FK-506 and CsA, highlights the ability of both of these agents to disrupt binding between components of steroid hormone receptor complexes (Hsp-90 and p23) [42, 43] [28, 30] 
